Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isotretinoin oral adhesive film
- Development stage
- Discontinued
- Lead developer
- Skyline Biosciences
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
SBS-101 is an isotretinoin oral adhesive film developed by Skyline Biosciences for the treatment of oral premalignant lesions. It was designed to be applied directly to oral lesions, with the clinical trial aiming to evaluate its safety, pharmacokinetics, and efficacy on oral pre-malignant lesions.
02
Targets
RARG (Retinoic acid receptor gamma)RARA (Retinoic acid receptor alpha)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on isotretinoin oral adhesive film.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isotretinoin oral adhesive film.